Our study demonstrated that RASSF6 plays an important role in the cellular response to cisplatin and radiation treatment; therefore, RASSF6 could be used as a potential biomarker of NPC for predicting treatment response. The gene discussed is RASSF6; the disease is nasopharyngeal carcinoma.